A fairly recent article that talks about ADCC is Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer .-- JWSchmidt 22 : 54, 8 December 2006 ( UTC)
22.
Since 1998, Patrick Baeuerle investigates the therapeutic potential of T cell-engaging BiTE antibodies for therapy of cancer, and has been responsible at Micromet for the development of blinatumomab and several other antibody therapies.
23.
Today, Mitch Sayare, chief executive of ImmunoGen, a Cambridge, Mass . company that specializes in monoclonal antibody treatments for cancer, said many of the 402 cancer treatments now in development are antibody therapies.
24.
MassBiologics, a non-profit organization engaged in the discovery, development and manufacturing of biologic therapies, is cooperating with researchers at NIH and the CDC developed a monoclonal antibody therapy that demonstrated efficacy in animal models.
25.
Another phase I clinical trial has reported a dose-dependent inhibition of IFN-? / ?-inducible genes in both peripheral blood and skin biopsies in SLE patients treated with anti-IFN monoclonal antibody therapy.
26.
Technologies developed in her laboratory and that of Dr . Andreas Herrmann at City of Hope are being used by a newly formed company, LA Cell, Inc ., which hopes to develop cell-penetrating antibody therapies.
27.
The antisense field anticipated that the approval of fomivirsen marked the beginning of a new age of antisense drug treatments, that would be similar to the uptake of monoclonal antibody therapy, but the next FDA approval of an antisense drug came in 2013.
28.
"' MDX-1097 "'( also called "'IST-1097 "') is a monoclonal antibody therapy being assessed in clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer.
29.
Cell surface receptors are common targets for antibody therapies and include CD20, CD274 and CD279 . Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death.
